Jade Biosciences Inc (JBIO)

$18.49 +0.60 (3.35%)
Market Cap 882.26M
Revenue (ttm) 0.00
Net Income (ttm) -127.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 784,800
Avg Vol 446,594
Day's Range N/A - N/A
Shares Out 49.32M
Stochastic %K 92%
Beta 1.03
Analysts Strong Sell
Price Target $28.25

Company Profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The compnay also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences,...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 312 3013
Address:
Building 23, Suite 105 221 Crescent Street, Waltham, United States
focafoca99
focafoca99 Apr. 3 at 8:30 PM
$JBIO approved a 2026 inducement equity plan for future new-hire awards.
0 · Reply
kshonstocks
kshonstocks Apr. 1 at 3:31 PM
good early volume $JBIO
1 · Reply
Abron
Abron Mar. 24 at 4:09 PM
$JBIO whats happening? why is the stock falling?
0 · Reply
erevnon
erevnon Mar. 16 at 11:07 AM
BTIG maintains Jade Biosciences $JBIO at Buy and raises the price target from $28 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Mar. 11 at 11:22 AM
Guggenheim maintains Jade Biosciences $JBIO at Buy and raises the price target from $17 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Abron
Abron Feb. 25 at 4:09 PM
$JBIO every day the same thing
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 12:29 PM
$JBIO Current Stock Price: $14.44 Contracts to trade: $15.0 JBIO Feb 20 2026 Call Entry: $1.08 Exit: $1.39 ROI: 29% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 11:27 AM
$JBIO RSI: 40.24, MACD: 0.1000 Vol: 0.83, MA20: 15.49, MA50: 14.88 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TradeIntelligence_
TradeIntelligence_ Feb. 11 at 12:47 PM
Will $JBIO's conference participation signal a sector rotation? Jade Biosciences announces upcoming presentations. Risk management remains paramount for biotech investors amid shifting market dynamics.
0 · Reply
TrendInsight
TrendInsight Feb. 4 at 3:30 PM
$JBIO is a biotech company; without specifics, it is a high-risk investment dependent on the success of its preclinical or clinical pipeline.
0 · Reply
Latest News on JBIO
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 6, 2026, 7:00 AM EST - 5 weeks ago

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Upcoming Conferences

Feb 11, 2026, 7:00 AM EST - 2 months ago

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 3 months ago

Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

Jade Biosciences Announces $45 Million Private Placement

Dec 15, 2025, 7:00 AM EST - 4 months ago

Jade Biosciences Announces $45 Million Private Placement

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:05 PM EST - 5 months ago

Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Nov 8, 2025, 11:00 AM EST - 5 months ago

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Oct 17, 2025, 4:05 PM EDT - 6 months ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Oct 7, 2025, 7:05 AM EDT - 6 months ago

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

Jade Biosciences Announces $135 Million Private Placement

Oct 7, 2025, 7:00 AM EDT - 6 months ago

Jade Biosciences Announces $135 Million Private Placement

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Sep 2, 2025, 7:00 AM EDT - 7 months ago

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 4:05 PM EDT - 8 months ago

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jul 8, 2025, 7:00 AM EDT - 9 months ago

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jul 1, 2025, 7:00 AM EDT - 10 months ago

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jun 9, 2025, 7:00 AM EDT - 11 months ago

Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jun 2, 2025, 7:00 AM EDT - 11 months ago

Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:05 PM EDT - 11 months ago

Jade Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 11 months ago

Jade Biosciences to Participate in the 2025 Jefferies Global Healthcare Conference

focafoca99
focafoca99 Apr. 3 at 8:30 PM
$JBIO approved a 2026 inducement equity plan for future new-hire awards.
0 · Reply
kshonstocks
kshonstocks Apr. 1 at 3:31 PM
good early volume $JBIO
1 · Reply
Abron
Abron Mar. 24 at 4:09 PM
$JBIO whats happening? why is the stock falling?
0 · Reply
erevnon
erevnon Mar. 16 at 11:07 AM
BTIG maintains Jade Biosciences $JBIO at Buy and raises the price target from $28 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
erevnon
erevnon Mar. 11 at 11:22 AM
Guggenheim maintains Jade Biosciences $JBIO at Buy and raises the price target from $17 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Abron
Abron Feb. 25 at 4:09 PM
$JBIO every day the same thing
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 12:29 PM
$JBIO Current Stock Price: $14.44 Contracts to trade: $15.0 JBIO Feb 20 2026 Call Entry: $1.08 Exit: $1.39 ROI: 29% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 11:27 AM
$JBIO RSI: 40.24, MACD: 0.1000 Vol: 0.83, MA20: 15.49, MA50: 14.88 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
TradeIntelligence_
TradeIntelligence_ Feb. 11 at 12:47 PM
Will $JBIO's conference participation signal a sector rotation? Jade Biosciences announces upcoming presentations. Risk management remains paramount for biotech investors amid shifting market dynamics.
0 · Reply
TrendInsight
TrendInsight Feb. 4 at 3:30 PM
$JBIO is a biotech company; without specifics, it is a high-risk investment dependent on the success of its preclinical or clinical pipeline.
0 · Reply
Quantumup
Quantumup Jan. 16 at 6:23 PM
Cantor reiterated Top Pick $VERA Overweight; $100. $TVTX $NVS OTSKY $JBIO VRTX AZN $IONS RHHBY Here's what Cantor had to say: We caught up with VERA, a "Top Pick," and discussed atacicept's (APRIL/BAFF inh; BTD) potential approval in IgA nephropathy (IgAN) and commercial launch preparations... Our overall takeaway is that all the pieces are in place for a successful regulatory outcome as VERA lays the framework for a strong commercial launch.
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 16 at 5:29 PM
$JBIO Current Stock Price: $15.11 Contracts to trade: $15 JBIO Jan 16 2026 Call Entry: $1.13 Exit: $1.56 ROI: 37% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
notreload_ai
notreload_ai Jan. 7 at 3:23 PM
$LEGN , $JBIO , $CGEN ... Oppenheimer and H.C. Wainwright start coverage on Legend Biotech, Jade Biosciences, and Compugen with bullish ratings and price targets, highlighting growth potential in CAR-T therapy, autoimmune, and immuno-oncology pipelines. https://notreload.xyz/oppenheimer-hc-wainwright-bullish-on-leg-jbio-cgen/
0 · Reply
garygb
garygb Jan. 5 at 3:24 PM
$JBIO Like the price better now.
0 · Reply
OGUZATA
OGUZATA Dec. 20 at 11:18 PM
$JBIO It is a critical point, it must be followed carefully moment by moment.
0 · Reply
stayput
stayput Dec. 17 at 4:47 AM
$JBIO Up 32% after reverse split in April. I don’t fold . Avg $12.37. More money will be made imo. Takes some coins to hold imo. NFA
0 · Reply
Trade_Master26
Trade_Master26 Dec. 15 at 11:17 PM
$JBIO perking
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 9:04 PM
$JBIO Share Price: $13.49 Contract Selected: May 15, 2026 $10 Calls Buy Zone: $2.12 – $2.62 Target Zone: $3.98 – $4.87 Potential Upside: 77% ROI Time to Expiration: 156 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply